Publications in collaboration with researchers from University of Milano-Bicocca (31)

2024

  1. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

2023

  1. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

    Cancers, Vol. 15, Núm. 13

  2. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

  3. Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617

  4. Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Obstetrical and Gynecological Survey

2022

  1. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

2021

  1. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

    International Journal of Gynecological Cancer, Vol. 31, Núm. 4, pp. 617-622

  2. Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159] (Annals of Oncology (2020) 31(9) (1148–1159), (S0923753420398914), (10.1016/j.annonc.2020.06.004))

    Annals of Oncology

  3. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

    Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190

  4. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    Radiotherapy and Oncology, Vol. 154, pp. 327-353

  5. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

    International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39

  6. Maintenance treatment of newly diagnosed advanced ovarian cancer: Time for a paradigm shift?

    Cancers, Vol. 13, Núm. 22

  7. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 632-642

  8. The systemic treatment of recurrent ovarian cancer revisited

    Annals of Oncology, Vol. 32, Núm. 6, pp. 710-725

2020

  1. Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial

    Journal of Clinical Oncology, Vol. 38, Núm. 30, pp. 3528-3537

  2. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer

    Gynecologic Oncology, Vol. 159, Núm. 1, pp. 142-149

  3. Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment

    International Journal of Gynecological Cancer, Vol. 30, Núm. 10, pp. 1603-1607

  4. The forefront of ovarian cancer therapy: update on PARP inhibitors

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1148-1159

2019

  1. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  2. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428